DOCSLIB.ORG

1 Inventory of Supplemental Information Presented in Relation To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Inventory of Supplemental Information Presented in Relation To Inventory of Supplemental Information presented in relation to each of the main figures in the manuscript 1. Figure S1. Related to Figure 1. 2. Figure S2. Related to Figure 2. 3. Figure S3. Related to Figure 3. 4. Figure S4. Related to Figure 4. 5. Figure S5. Related to Figure 5. 6. Figure S6. Related to Figure 6. 7. Figure S7. Related to Figure 7. 8. Table S1. Related to Figures 1 and S1. 9. Table S2. Related to Figures 3, 4, 6 and 7. 10. Table S3. Related to Figure 3. Supplemental Experimental Procedures 1. Patients and samples 2. Cell culture 3. Long term culture-initiating cells (LTC-IC) assay 4. Differentiation of CD34+ cord blood cells 5. Bi-phasic erythroid differentiation assay 6. Clonal assay 7. Mutation and sequencing analysis 8. Bisulphite sequencing and quantitative pyrosequencing 9. Human SNP genotyping 10. Strand-specific cDNA synthesis and PCR 11. Chromatin Immuno-precipitation (ChIP) 12. Immunoprecipitation and western blot 13. Colony genotyping 14. shRNA generation and viral infection 15. Retrovirus generation and transduction 16. Study approval 17. Statistical Methods 18. Primers list Supplementary References (19) 1 Additional SGK2 families 2 3 4 ♂ ♀ ♂ ♀ ♂ ♀ C/G C/C C/C C/G C/C C/G ♀ ♀ ♂ ♀ C/G C/G C/G C/G T T C T G C T A G A T T C T C C T A G A T T C T C C T A G A T T C T C C T A G A T-Cells T-Cells T-Cells T-Cells Additional GDAP1L1 familiy 2 ♂ ♀ G/G A/A ♀ G/A A C A C G G T G Erythroblasts Figure S1 - . )4126 ;-,,-</ L%)K$L( O"I' "=#+(L( L%)K$L # # # # " " ! ! !! # " $"" # ! ! ! ! $ # ! $ " ! !# $ ! # # ! " " # $ " " " "6@4:7EG=H# "6@4:7EG=H# ?6-JGE=H# K3-7@GE=H# K)GE=H# *4,NGO-EGE=H# +K)H!GE=H# / )-E-F16 L%)K$L( O"I' PBQPR )( PBQPR )( # # # # ! $ " "" ! ! $ " "" ! #!!! " $ " $ # !!! " $ " $ ! ! "6@4:7EG=H# I7J@6/GE=H# L7M63GE=H# ;K!GE=H# 0 +34.4.5637- +,-./012 904221: )6.-.5637- C% (AA ;-,,-</ =4> (BC $5637- )4126 DD D' 81.5637- )-E-F16 '' ?1:-@ %&& '&& (&& & )*# !"#$%&'() *+#&', " 89:;"8< =$%( 2( 2& 2<9 2(B 2< 29 &%I # ; ! C9 C& 89:;"8<GS,-->-2+K1L>1)*+3/)5U13>N7:OP<&BMD>*+R>7:OP9(<PMQ 89:;"8<G*-12)+*15V2>1)*+3/)5U1>N+.>*//2335.+>+.TQ 89:;"8<G3L.)1>S.)4>1)*+3/)5U1>N#8<<P(MEQ :;"< :;"( :;"9 !(H! =# J,-->-2+K1L>G>MM(** : N7COP&'(E9Q :;"< C)2R5/12R>3L.)1>S.)4><>G>9(9** N+.>*//2335.+>+.TQ :;" :;"9 !(H! =# C)2R5/12R>3L.)1>S.)4>(>G>9EP** >>( : N+.>*//2335.+>+.TQ %&'( H7"9B ! - %&'( $)*+,-./0123 ! ! ! # " $ $2+.45/ 67# G>!.+1).- G>!.+1).- " " =2+32>/67# C)542)>/.+1).-? =2+32>/67##+1532+32>/67#C)542)>/.+1).-? #+1532+32>/67# 89:;"8< @A><9 =2+32>?7# @A><D 89:;"8< #+1532+32>?7# @A <EF(< @A>(B C9 C& < 9:2%)42*; 6(P=<<<&<>>>>>>>>6(P=B''>>>>>>>>>>>6(P=<&P>>>>> # <TP PTD !.+ PT' PTB ;: PT( ?2-*15V2>2AU)2335.+ PTP 7G< 7G( C1G< C1G' %&'( H7"9B !.*/*0)1)2%34* 566 78 77 $%&'()*+, 3 !"#$%&#'((' . =67>"?') 2)5:((D('''''2)5:((<'''''' (5A555 (A555 /'B%??C (55 3.+ ' (5 ( "C'I'68 5@( 17"& E%?"#$F%'%GH7%CC$6& 5@5( 9 1- 9 1- 9 1- 9 1- 9 1- +,-./+( :1;) 123!(+( -0.. 4)5678((( 2%?'B6?C 4 2 !"#$%&#'*' !"#$%&#'<' (5A555 (5A555 (A555 (A555 3.+ (55 ' (55 (5 (5 ( "C'I'68 ( 5@( E%?"#$F%'%GH7%CC$6& 5@( ' 5@5( 5@5( =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? ' +,-./+(123!(+( -0.. 4)5678((( +,-./+(123!(+( -0.. 4)5678((( 9 O !"#$%&#'()'' !"#$%&#'(, (5A555 (5A555 (A555 (A555 (55 (55 3.+ ' (5 (5 ( ( "C'I'68 5@( 5@( E%?"#$F%'%GH7%CC$6& 5@5( 5@5( =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? +,-./+(123!(+( -0.. 4)5678((( +,-./+(123!(+( -0.. 4)5678((( 1 P (5A555 !"#$%&#'(JK97L#M76$N (5A555 !"#$%&#'(JK-L%?6$N (A555 (A555 (55 (55 3.+ ' (5 (5 ( ( "C'I'68 5@( 5@( E%?"#$F%'%GH7%CC$6& 5@5( 5@5( =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? =6 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? 2%? +,-./+(123!(+( -0.. 4)5678((( +,-./+(123!(+( -0.. 4)5678((( !"#$%&'() + 0,(120/ !"#$ 01@;4? ;)A8%&' ?67)& ;B48CC)&=<% %&' 1. 6 ()* 0.04 ()* 1. 2 0.03 0.8 0.02 0.4 0.01 0.0 0.00 + D E /$ + D E /$ 285);FG6'CH * 0,(120/ !"#$ /$+ ! %&' ! %&' ! ()* ! ()* .+ -+ ,+ + 34&56789):;%<=>;&)7>;?4;@10 Scr-shRNA Scr-shRNA Scr-shRNA Scr-shRNA L3-shRNA1L3-shRNA2 L3-shRNA1L3-shRNA2 S2-shRNA1S2-shRNA2 S2-shRNA1S2-shRNA2 W . "UT !I&JCKL3@ !I&JCKL3@ /++P 0,JCKL3@$ !$JCKL3@$ W VV RQP VV VV VV W Q+P $QP ;SGR/;"T@ +P !I&JCKL3@ !I&JCKL3@ W 0,JCKL3@$ !$JCKL3@$ -+P VV DQP VV W ,+P VV VV /QP SGD/;SG-/ +P D E /$ D E /$ 285);FG6'CH , M1@ M11 - *=NO 01@;4? ; > 7)& ; >=<%;:)98 765&43 D D 01@;4?D ;)A8 ?67)& ;B48CC)&=<% , , , $ $ $ / / / + + + !I&JCKL3@0,JCKL3@/!$JCKL3@/ !I&JCKL3@0,JCKL3@/!$JCKL3@/ !I&JCKL3@0,JCKL3@/!$JCKL3@/ !"#$%&'() A Phase&I&Culture + + + GFP GFP&CFP ScrAshRNA ScrAshRNA ScrAshRNA Day&0 Day&14 L3AshRNA1 S2AshRNA1 DiAshRNA 100% + 75% 50% CD71 Phase&I 25% CD71 0% GPA Phase&II&Culture Day&2 Day&14 100% + 75% 50% GPA 25% Phase&II 0% CD71 2 6 10 14 2 6 10 14 2 6 10 14 GPA Time&(Days) Phase&I + + + + + B GFP&CD71 GFP&CFP&CD71 40% * ** ScrAshRNA L3AshRNA1 S2AshRNA1 DiAshRNA 35% * * 13.8 27.3 20.5 32.1 20% 1.37 4.01 1.81 6.31 10% SAPhase&cells 84.1 67.9 77.1 61.1 BrdU 0% 7AAD L3+S2 rAshRNA AshRNA1 c 3 2AshRNA1 AshRNA Phase&I + + + + + S L S C GFP&CD71 GFP&CFP&CD71 16% ScrAshRNA L3AshRNA1 S2AshRNA1 DiAshRNA + 88.1 6.7 88.4 2.5 76.5 12 85.8 9.3 12% 8% + 4% 4.5 0.2 9.0 0.1 11.1 0.4 4.9 0 7AAD&Anx&V& 0% Annexin&V 7AAD L3+S2 rAshRNA AshRNA1 c 3 2AshRNA1 shRNA S L S 0.0M&5AAC D E F G 0.10 0.8 L3MBTL1 EV L3MBTL1 0.3 HBA 0.2M&5AAC 0.08 0.5M&5AAC 0.6 ABL 0.2 0.06 0.4 0.04 0.1 0.2 0.02 Exp.&rel.&to& Exp.&rel.&to&ABL Exp.&rel.&to&ABL 0 0.0 0.00 L3MBTL1 SGK2 H 0.20 SGK2 SGK2 L3MBTL1&& 0.5 HBB 150 Number&of&cells SGK2 0.15 120 0.3 90 0.10 60 0.05 0.1 GPA&(MFI) 30 Exp.&rel.&to&ABL Exp.&rel.&to&ABL 0.00 0.0 0 EV M M M K562HEL GPA 0 SGK2 SGK2 0.2 0.5 L3MBTL1 Uninduced& Uninduced A UninducedL3MBTL1 Uninduced GFP ! Empty&vector 50M&Hemin + 50M& L3MBTL1&+&SGK2 GFP L3MBTL1&&&SGK2 &&+&5AAC + + Hemin 50M&Hemin GFP&CFP induction &induction 50M&Hemin &induction &&induction Figure(S6 ((Page(1 I CFU5GM 80 5 BFU5E 40 CFU5GEMM 4 60 30 3 40 20 2 20 1 10 0 0 0 Colonies/1000/cells L3+S2 L3+S2 L3+S2 r5shRNA 5shRNA1 r5shRNA 5shRNA1 r5shRNA 5shRNA1 c 25shRNA1 5shRNA c 25shRNA1 shRNA c 25shRNA1 shRNA S L3 S S L3 S S L3 S J K 15 CFU5S 150 L3mbtl1 Sgk2 120 12 90 9 60 6 30 3 0 Colonies/spleen 0 relative/to/GapdH Normalised/expression 5shRNA 5shRNA5shRNA r5shRNA 25shRNA cr 25shRNA Uninfectedc L3 S S L3 S mL3+mS2 S m m m m Scr25shRNA shRNA L M 150 L3mbtl1 H LSK d 2.0 2.5 CMP p 120 a G 90 2.0 / 1.5 t o t s / 1.5 o e 60 v 1.0 i H t + 1.0 a r l 30 e o r t 0.5 / i t 0.5 n 0 e o i p s 0.0 0.0 s 150 Sgk2 m e o r p 120 C 2.0 GMP MEP / x r e / o d 90 n 1.5 e o s i D l 60 a 1.0 m r 30 o N 0 0.5 0.0 5shRNA5shRNA5shRNA5shRNA cr 3 2 2 25shRNA L S cr S S m + m S 3 L 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA m r 3 2 2 25shRNA r 3 2 2 25shRNA c L S r S c L S r S S c + S c + m m S 3 m m S 3 L L N m m + + + 2.0 BM/B220 BM/CD71 BM/Mac51 1.5 t s o 1.0 H + r o t 0.5 i t e p 0.0 m o Spleen/B220+ + + C 1.5 Spleen/Mac51 Thymus/CD3 / r o n o 1.0 D 0.5 0.0 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA 5shRNA r 3 2 2 25shRNA r 3 2 2 25shRNA r 3 2 2 25shRNA c L S r S c L S r S c L S r S S c + S c + S c + m m S 3 m m S 3 m m S 3 L L L m m m Figure*S6 **Page*2 A 12 MYC 12 ABL 8 8 4 4 Exp.@rel.@ 0 0 L3+S2 L3+S2 )shRNA )shRNA Scr)shRNA Scr)shRNA L3)shRNA2 S2)shRNA3 L3)shRNA1S2)shRNA2 B ph)S2)PolII 3000 6000 2000 4000 1000 2000 0 0 Fold@enrch.@rel.@to@IgG L3+S2 L3+S2 )shRNA Scr)shRNA )shRNA Scr)shRNA L3)shRNA1S2)shRNA1 L3)shRNA1S2)shRNA2 C H3K4me3 2500 3000 2000 2400 1500 1800 1000 1200 500 600 0 0 Fold@enrch.@rel.@to@IgG L3+S2 L3+S2 Scr)shRNA )shRNA Scr)shRNA )shRNA L3)shRNA1S2)shRNA1 L3)shRNA1S2)shRNA1 D L3MBTL1 250 200 200 160 150 120 100 80 50 40 0 0 Fold@enrch.@rel.@to@IgG L3+S2 L3+S2 )shRNA )shRNA Scr)shRNAL3)shRNA1 S2)shRNA1 Scr)shRNAL3)shRNA1 S2)shRNA1 E BRG1 1000 2500 800 2000 600 1500 400 1000 200 500 0 0 Fold@enrch.@rel.@to@IgG L3+S2 L3+S2 )shRNA )shRNA Scr)shRNAL3)shRNA1S2)shRNA1 Scr)shRNAL3)shRNA1S2)shRNA1 F BRG1 900 750 600 500 300 250 0 0 Fold@enrch.@rel.@to@IgG SGK2 SGK2 Empty@vector Empty@vector Figure'S7 Figure S1.
Load more

Recommended publications
  • Cooperativity of Imprinted Genes Inactivated by Acquired Chromosome 20Q Deletions
    Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz, … , Anne C. Ferguson-Smith, Anthony R. Green J Clin Invest. 2013;123(5):2169-2182. https://doi.org/10.1172/JCI66113. Research Article Oncology Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primate-restricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprinted gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of genomic loss, and underline the complex molecular and cellular consequences of “simple” cancer-associated chromosome deletions. Find the latest version: https://jci.me/66113/pdf Research article Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions Athar Aziz,1,2 E. Joanna Baxter,1,2,3 Carol Edwards,4 Clara Yujing Cheong,5 Mitsuteru Ito,4 Anthony Bench,3 Rebecca Kelley,1,2 Yvonne Silber,1,2 Philip A.
    [Show full text]
  • Genome-Wide Parent-Of-Origin DNA Methylation Analysis Reveals The
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Research Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment Franck Court,1,15 Chiharu Tayama,2,15 Valeria Romanelli,1,15 Alex Martin-Trujillo,1,15 Isabel Iglesias-Platas,3 Kohji Okamura,4 Naoko Sugahara,2 Carlos Simo´n,5 Harry Moore,6 Julie V. Harness,7 Hans Keirstead,7 Jose Vicente Sanchez-Mut,8 Eisuke Kaneki,9 Pablo Lapunzina,10 Hidenobu Soejima,11 Norio Wake,9 Manel Esteller,8,12,13 Tsutomu Ogata,14 Kenichiro Hata,2 Kazuhiko Nakabayashi,2,16,17 and David Monk1,16,17 1–14[Author affiliations appear at the end of the paper.] Differential methylation between the two alleles of a gene has been observed in imprinted regions, where the methylation of one allele occurs on a parent-of-origin basis, the inactive X-chromosome in females, and at those loci whose methylation is driven by genetic variants. We have extensively characterized imprinted methylation in a substantial range of normal human tissues, reciprocal genome-wide uniparental disomies, and hydatidiform moles, using a combination of whole- genome bisulfite sequencing and high-density methylation microarrays. This approach allowed us to define methylation profiles at known imprinted domains at base-pair resolution, as well as to identify 21 novel loci harboring parent-of-origin methylation, 15 of which are restricted to the placenta. We observe that the extent of imprinted differentially methylated regions (DMRs) is extremely similar between tissues, with the exception of the placenta.
    [Show full text]
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity
    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between
    [Show full text]
  • Imprinting of the Human L3MBTL Gene, a Polycomb Family Member Located in a Region of Chromosome 20 Deleted in Human Myeloid Malignancies
    Correction GENETICS Correction for “Imprinting of the human L3MBTL gene, a poly- The authors note that a mistake occurred during the prepa- comb family member located in a region of chromosome 20 deleted ration of Fig. 1B. Three control lanes (6, 7, and 8) were inad- in human myeloid malignancies,” by Juan Li, Anthony J. Bench, vertently duplicated and also shown as lanes 3, 4, and 5. This George S. Vassiliou, Nasios Fourouclas, Anne C. Ferguson-Smith, resulted from a technical error during preparation of the figure and Anthony R. Green, first published April 30, 2004; 10.1073/ and does not alter any of the conclusions of the paper. The pnas.0308195101 (Proc. Natl. Acad. Sci. U.S.A. 101, 7341–7346). corrected figure and the unaltered figure legend appear below. A CORRECTION B C Fig. 1. Allelic methylation of the L3MBTL gene. (A) Locus of the L3MBTL gene and intron/exon structure of its 5′ and 3′ regions. Coding and noncoding exons are shown in black and gray boxes, respectively. Bent arrows indicate two putative promoters. Patterned horizontal bars represent the four CpG islands. Asterisks indicate the locations of SNPs used in the study, and primers spanning the respective SNPs are indicated (P1–P8). (B) Methylation analysis of the CpG island 3 by using SSCP. Lane 1, universally methylated genomic control DNA; lanes 2–5, normal bone marrow; lanes 6–9, normal granulocytes; lanes 10–13, granulocytes from patients, with an acquired 20q deletion. (C) Bisulfite sequencing of CpG island 3. Sequences relate to samples corresponding to individual lanes from B, as indicated.
    [Show full text]
  • Expression Analysis of Genes Located Within the Common Deleted Region
    Leukemia Research 84 (2019) 106175 Contents lists available at ScienceDirect Leukemia Research journal homepage: www.elsevier.com/locate/leukres Research paper Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes T ⁎ Masayuki Shiseki , Mayuko Ishii, Michiko Okada, Mari Ohwashi, Yan-Hua Wang, Satoko Osanai, Kentaro Yoshinaga, Naoki Mori, Toshiko Motoji, Junji Tanaka Department of Hematology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan ARTICLE INFO ABSTRACT Keywords: Deletion of the long arm of chromosome 20 (del(20q)) is observed in 5–10% of patients with myelodysplastic Deletion 20q syndromes (MDS). We examined the expression of 28 genes within the common deleted region (CDR) of del Common deleted region (20q), which we previously determined by a CGH array using clinical samples, in 48 MDS patients with (n = 28) Myelodysplastic syndromes or without (n = 20) chromosome 20 abnormalities and control subjects (n = 10). The expression level of 8 of 28 genes was significantly reduced in MDS patients with chromosome 20 abnormalities compared to that of control subjects. In addition, the expression of BCAS4, ADA, and YWHAB genes was significantly reduced in MDS pa- tients without chromosome 20 abnormalities, which suggests that these three genes were commonly involved in the molecular pathogenesis of MDS. To evaluate the clinical significance, we analyzed the impact of the ex- pression level of each gene on overall survival (OS). According to the Cox proportional hazard model, multi- variate analysis indicated that reduced BCAS4 expression was associated with inferior OS, but the difference was not significant (HR, 3.77; 95% CI, 0.995-17.17; P = 0.0509).
    [Show full text]
  • Proteomic Expression Profile in Human Temporomandibular Joint
    diagnostics Article Proteomic Expression Profile in Human Temporomandibular Joint Dysfunction Andrea Duarte Doetzer 1,*, Roberto Hirochi Herai 1 , Marília Afonso Rabelo Buzalaf 2 and Paula Cristina Trevilatto 1 1 Graduate Program in Health Sciences, School of Medicine, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba 80215-901, Brazil; [email protected] (R.H.H.); [email protected] (P.C.T.) 2 Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru 17012-901, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-41-991-864-747 Abstract: Temporomandibular joint dysfunction (TMD) is a multifactorial condition that impairs human’s health and quality of life. Its etiology is still a challenge due to its complex development and the great number of different conditions it comprises. One of the most common forms of TMD is anterior disc displacement without reduction (DDWoR) and other TMDs with distinct origins are condylar hyperplasia (CH) and mandibular dislocation (MD). Thus, the aim of this study is to identify the protein expression profile of synovial fluid and the temporomandibular joint disc of patients diagnosed with DDWoR, CH and MD. Synovial fluid and a fraction of the temporomandibular joint disc were collected from nine patients diagnosed with DDWoR (n = 3), CH (n = 4) and MD (n = 2). Samples were subjected to label-free nLC-MS/MS for proteomic data extraction, and then bioinformatics analysis were conducted for protein identification and functional annotation. The three Citation: Doetzer, A.D.; Herai, R.H.; TMD conditions showed different protein expression profiles, and novel proteins were identified Buzalaf, M.A.R.; Trevilatto, P.C.
    [Show full text]
  • Genomic Analyses Implicate Noncoding De Novo Variants in Congenital Heart Disease
    Lawrence Berkeley National Laboratory Recent Work Title Genomic analyses implicate noncoding de novo variants in congenital heart disease. Permalink https://escholarship.org/uc/item/1ps986vj Journal Nature genetics, 52(8) ISSN 1061-4036 Authors Richter, Felix Morton, Sarah U Kim, Seong Won et al. Publication Date 2020-08-01 DOI 10.1038/s41588-020-0652-z Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 December 29. Published in final edited form as: Nat Genet. 2020 August ; 52(8): 769–777. doi:10.1038/s41588-020-0652-z. Genomic analyses implicate noncoding de novo variants in congenital heart disease Felix Richter1,31, Sarah U. Morton2,3,31, Seong Won Kim4,31, Alexander Kitaygorodsky5,31, Lauren K. Wasson4,31, Kathleen M. Chen6,31, Jian Zhou6,7,8, Hongjian Qi5, Nihir Patel9, Steven R. DePalma4, Michael Parfenov4, Jason Homsy4,10, Joshua M. Gorham4, Kathryn B. Manheimer11, Matthew Velinder12, Andrew Farrell12, Gabor Marth12, Eric E. Schadt9,11,13, Jonathan R. Kaltman14, Jane W. Newburger15, Alessandro Giardini16, Elizabeth Goldmuntz17,18, Martina Brueckner19, Richard Kim20, George A. Porter Jr.21, Daniel Bernstein22, Wendy K. Chung23, Deepak Srivastava24,32, Martin Tristani-Firouzi25,32, Olga G. Troyanskaya6,7,26,32, Diane E. Dickel27,32, Yufeng Shen5,32, Jonathan G. Seidman4,32, Christine E. Seidman4,28,32, Bruce D. Gelb9,29,30,32,* 1Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
    [Show full text]
  • Mai Muudatuntuu Ti on Man Mini
    MAIMUUDATUNTUU US009809854B2 TI ON MAN MINI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,809 ,854 B2 Crow et al. (45 ) Date of Patent : Nov . 7 , 2017 Whitehead et al. (2005 ) Variation in tissue - specific gene expression ( 54 ) BIOMARKERS FOR DISEASE ACTIVITY among natural populations. Genome Biology, 6 :R13 . * AND CLINICAL MANIFESTATIONS Villanueva et al. ( 2011 ) Netting Neutrophils Induce Endothelial SYSTEMIC LUPUS ERYTHEMATOSUS Damage , Infiltrate Tissues, and Expose Immunostimulatory Mol ecules in Systemic Lupus Erythematosus . The Journal of Immunol @(71 ) Applicant: NEW YORK SOCIETY FOR THE ogy , 187 : 538 - 552 . * RUPTURED AND CRIPPLED Bijl et al. (2001 ) Fas expression on peripheral blood lymphocytes in MAINTAINING THE HOSPITAL , systemic lupus erythematosus ( SLE ) : relation to lymphocyte acti vation and disease activity . Lupus, 10 :866 - 872 . * New York , NY (US ) Crow et al . (2003 ) Microarray analysis of gene expression in lupus. Arthritis Research and Therapy , 5 :279 - 287 . * @(72 ) Inventors : Mary K . Crow , New York , NY (US ) ; Baechler et al . ( 2003 ) Interferon - inducible gene expression signa Mikhail Olferiev , Mount Kisco , NY ture in peripheral blood cells of patients with severe lupus . PNAS , (US ) 100 ( 5 ) : 2610 - 2615. * GeneCards database entry for IFIT3 ( obtained from < http : / /www . ( 73 ) Assignee : NEW YORK SOCIETY FOR THE genecards. org /cgi - bin / carddisp .pl ? gene = IFIT3 > on May 26 , 2016 , RUPTURED AND CRIPPLED 15 pages ) . * Navarra et al. (2011 ) Efficacy and safety of belimumab in patients MAINTAINING THE HOSPITAL with active systemic lupus erythematosus : a randomised , placebo FOR SPECIAL SURGERY , New controlled , phase 3 trial . The Lancet , 377 :721 - 731. * York , NY (US ) Abramson et al . ( 1983 ) Arthritis Rheum .
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • Cellular Functions of Genetically Imprinted Genes in Human and Mouse As Annotated in the Gene Ontology
    Cellular Functions of Genetically Imprinted Genes in Human and Mouse as Annotated in the Gene Ontology Mohamed Hamed1, Siba Ismael1, Martina Paulsen2, Volkhard Helms1* 1 Center for Bioinformatics, Saarland University, Saarbru¨cken, Germany, 2 Department of Genetics, Saarland University, Saarbru¨cken, Germany Abstract By analyzing the cellular functions of genetically imprinted genes as annotated in the Gene Ontology for human and mouse, we found that imprinted genes are often involved in developmental, transport and regulatory processes. In the human, paternally expressed genes are enriched in GO terms related to the development of organs and of anatomical structures. In the mouse, maternally expressed genes regulate cation transport as well as G-protein signaling processes. Furthermore, we investigated if imprinted genes are regulated by common transcription factors. We identified 25 TF families that showed an enrichment of binding sites in the set of imprinted genes in human and 40 TF families in mouse. In general, maternally and paternally expressed genes are not regulated by different transcription factors. The genes Nnat, Klf14, Blcap, Gnas and Ube3a contribute most to the enrichment of TF families. In the mouse, genes that are maternally expressed in placenta are enriched for AP1 binding sites. In the human, we found that these genes possessed binding sites for both, AP1 and SP1. Citation: Hamed M, Ismael S, Paulsen M, Helms V (2012) Cellular Functions of Genetically Imprinted Genes in Human and Mouse as Annotated in the Gene Ontology. PLoS ONE 7(11): e50285. doi:10.1371/journal.pone.0050285 Editor: Osman El-Maarri, University of Bonn, Institut of experimental hematology and transfusion medicine, Germany Received June 23, 2012; Accepted October 23, 2012; Published November 30, 2012 Copyright: ß 2012 Hamed et al.
    [Show full text]
  • Drosophila and Human Transcriptomic Data Mining Provides Evidence for Therapeutic
    Drosophila and human transcriptomic data mining provides evidence for therapeutic mechanism of pentylenetetrazole in Down syndrome Author Abhay Sharma Institute of Genomics and Integrative Biology Council of Scientific and Industrial Research Delhi University Campus, Mall Road Delhi 110007, India Tel: +91-11-27666156, Fax: +91-11-27662407 Email: [email protected] Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 Running head: Pentylenetetrazole mechanism in Down syndrome 1 Abstract Pentylenetetrazole (PTZ) has recently been found to ameliorate cognitive impairment in rodent models of Down syndrome (DS). The mechanism underlying PTZ’s therapeutic effect is however not clear. Microarray profiling has previously reported differential expression of genes in DS. No mammalian transcriptomic data on PTZ treatment however exists. Nevertheless, a Drosophila model inspired by rodent models of PTZ induced kindling plasticity has recently been described. Microarray profiling has shown PTZ’s downregulatory effect on gene expression in fly heads. In a comparative transcriptomics approach, I have analyzed the available microarray data in order to identify potential mechanism of PTZ action in DS. I find that transcriptomic correlates of chronic PTZ in Drosophila and DS counteract each other. A significant enrichment is observed between PTZ downregulated and DS upregulated genes, and a significant depletion between PTZ downregulated and DS dowwnregulated genes. Further, the common genes in PTZ Nature Precedings : hdl:10101/npre.2010.4330.1 Posted 5 Apr 2010 downregulated and DS upregulated sets show enrichment for MAP kinase pathway. My analysis suggests that downregulation of MAP kinase pathway may mediate therapeutic effect of PTZ in DS. Existing evidence implicating MAP kinase pathway in DS supports this observation.
    [Show full text]
  • Ultraconserved Elements Are Associated with Homeostatic Control of Splicing Regulators by Alternative Splicing and Nonsense-Mediated Decay
    Downloaded from genesdev.cshlp.org on September 24, 2021 - Published by Cold Spring Harbor Laboratory Press Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay Julie Z. Ni,1 Leslie Grate,1 John Paul Donohue,1 Christine Preston,2 Naomi Nobida,2 Georgeann O’Brien,2 Lily Shiue,1 Tyson A. Clark,3 John E. Blume,3 and Manuel Ares Jr.1,2,4 1Center for Molecular Biology of RNA and Department of Molecular, Cell, and Developmental Biology, University of California at Santa Cruz, Santa Cruz, California 95064, USA; 2Hughes Undergraduate Research Laboratory, University of California at Santa Cruz, Santa Cruz, California 95064, USA; 3Affymetrix, Inc., Santa Clara, California 95051, USA Many alternative splicing events create RNAs with premature stop codons, suggesting that alternative splicing coupled with nonsense-mediated decay (AS-NMD) may regulate gene expression post-transcriptionally. We tested this idea in mice by blocking NMD and measuring changes in isoform representation using splicing-sensitive microarrays. We found a striking class of highly conserved stop codon-containing exons whose inclusion renders the transcript sensitive to NMD. A genomic search for additional examples identified >50 such exons in genes with a variety of functions. These exons are unusually frequent in genes that encode splicing activators and are unexpectedly enriched in the so-called “ultraconserved” elements in the mammalian lineage. Further analysis show that NMD of mRNAs for splicing activators such as SR proteins is triggered by splicing activation events, whereas NMD of the mRNAs for negatively acting hnRNP proteins is triggered by splicing repression, a polarity consistent with widespread homeostatic control of splicing regulator gene expression.
    [Show full text]